Quality of life and local treatment of oligometastatic prostate cancer

Share :
Published: 8 May 2019
Views: 1150
Prof Claude Abbou - Clinique de l'Alma, Paris, France

Prof Claude Abbou speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about quality of life after radical prostatectomy and local treatment in oligometastatic prostate cancer.

Prof Abbou explains the importance of understanding the patient's quality of life after surgery, but also to consider the impact on the patient's family too.

He also discusses the difficulty in treating advanced oligometastatic disease and how the primary tumour should be treated to reduce the risk of dissemination.


I had the HER2 main talks, one was on the quality of life of a couple after radical prostatectomy, which is a very interesting talk because the quality of life always in the scientific debate is just something not so important in terms of presentation and also interest. In this question of mostly prostatectomy, for example, or taking care of prostate cancer the quality of life of a patient is really essential – the patient thinks really about that more than other types of tumour. The problem is the quality of life of these patients is a combination between the patient himself but also the society around and mostly the partner, the wife. It’s a very important impact, including sometimes very severe impact that the risk of suicide for these patients is in some publications around 5%. Only the risk but of course it’s not the final situation.

We talked about that, we focussed about what to do and how to improve the relation between the doctor, the patient himself and also the partner or the wife. This is important, it’s very interesting, this kind of topic because it’s unusual.

The second talk was about the new paradigm or new data about what to do with advanced tumours but with oligometastatic, that means the patient having a small number of metastases. So the problem is to treat or not the primary tumour and this idea is a strong idea now. It’s observed now that when there is a small number of metastases the role of the primary tumour is probably important in terms of risk of dissemination as well as it’s probably very important to treat the primary tumour but also the other spots, usually a maximum of four or five spots, and this improves the survival of the patient. But you are really at the beginning of the information that we could have and could tell that we have to do it but we know that the orientation is probably that we will do it in the future to treat these patients like a patient having only the primary tumour involved in the process. So this is the main things.

This meeting is very interesting because the quality of people, of experts, are very high and it’s a hard time for the people listening to all the presentations because it’s a very high level and very strong data. The data now is increasing a lot and you have to find the right solution and the right idea in order to go towards the right direction.